Savior Lifetec announced on the 8th during its earnings call that its Q1 performance was boosted by the high demand for Ertapenem, increased revenues from its subsidiaries, and optimization of production capacity and processes. In addition, a gain from the sale of its Zhunan plant contributed NT$340 million. As a result, the gross profit margin rose from 30% to 37%, and the group's net profit attributable to the parent company reached NT$386 million, surpassing last year's full-year profit. The earnings per share (EPS) after tax was NT$1.22.
Furthermore, the Ertapenem formulation was successfully approved by the National Medical Products Administration (NMPA) in early April, marking its official entry into the Chinese market. The commercialization of the product will be handled by the prestigious distributor, China Resources Group's subsidiary "China Resources Jiuxin."
Savior Lifetec stated that it will continue to expand the global market for Ertapenem products with a positive momentum this year, while simultaneously strengthening its production capacity. The company plans to submit a change application for an additional production line in the second half of the year, preparing for further expansion of its global market share.
The company highlighted that, in the past, it has leveraged its operational advantages of upstream and downstream integration to independently develop and manufacture active pharmaceutical ingredients (APIs) and formulations, while also holding ANDA drug approvals. This has allowed it to successfully launch Meropenem formulations in the U.S., Europe, Southeast Asia, Taiwan, and nearly ten other countries. Drawing from this successful experience, the company has already strategically deployed its global Ertapenem market layout, successfully penetrating more than 20 countries, demonstrating its strong international competitiveness.
In Taiwan, Ertapenem has been widely adopted in several medical centers and regional hospitals, with the overall market share surpassing the original manufacturer, positioning the company as a market leader. At the same time, Savior Lifetec is working with a U.S. strategic marketing partner to actively pursue entry into another large GPO supply chain, positioning the company for strong future market growth.
Given the continued global demand for Ertapenem, Savior Lifetec has been expanding its production capacity. As the new capacity comes online, it will not only support global supply effectively but also inject strong momentum into the company's manufacturing capabilities and overall profitability.
In the CDMO sector, Savior Lifetec is currently the preferred partner for the global development and manufacturing of penem drugs. The company is collaborating with two major Japanese companies on API process development and injectable formulation outsourcing, laying a solid foundation for the growth of its CDMO business.
In addition to its core penem antibiotic business, its subsidiary SLC BioPharm and RZ Biotech are actively expanding their health and wellness business. They have established the SLC brand for health supplements, including products like Vitamin Bubbles, Hyaluronic Acid, Triple Calcium, Quick Energy, Vision Care, Jingmai Tong, and Stable Sugar. These products are sold through various channels, including chain drugstores, pharmacies, clinics, and e-commerce platforms in Taiwan, which is expected to further drive the group's revenue growth.
Resource: 松瑞藥第一季EPS 1.22元 賺贏去年全年
